As filed with the Securities and Exchange Commission on April 20, 2012
Registration Statement No. 333-151776

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 2

TO

FORM S-8

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

 

SeraCare Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Delaware
(State of Incorporation)
37 Birch Street
Milford, Massachusetts 01757
(617) 386-1000
33-0056054
(I.R.S. Employer Identification No.)

(Address of Registrant’s Principal Executive Offices)

 

Amended and Restated 2001 Stock Incentive Plan

Inducement Option Grants Outside of a Plan

(Full Title of the Plan)

 

Gregory A. Gould

Interim President and Chief Executive Officer and Chief Financial Officer

SeraCare Life Sciences, Inc.

37 Birch Street

Milford, Massachusetts 01757
(508) 244-6400

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:
John D. Hancock, Esq.
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
(617) 832-1000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o   Accelerated filer o   Non-accelerated filer o  

Smaller reporting

company þ

        (Do not check if a smaller reporting company)    

  

 
 

 

DEREGISTRATION OF COMMON STOCK

 

On June 19, 2008, the Registrant filed with the Securities and Exchange Commission a registration statement on Form S-8, Registration No. 333-151776 (the “Registration Statement”), as amended, for the sale of 1,582,980 shares of the common stock (the “Common Stock”), par value $.001 per share, of the Registrant under the Registrant’s Amended and Restated 2001 Stock Incentive Plan, 250,000 shares of Common Stock of the Registrant reserved for issuance upon the exercise of options granted on August 16, 2006 to Gregory A. Gould in connection with his employment, and 450,000 shares of Common Stock of the Registrant reserved for issuance upon the exercise of options granted on July 14, 2006 to Susan L.N. Vogt in connection with her employment.

 

On April 20, 2012, pursuant to the terms of the Agreement and Plan of Merger, dated as of February 12, 2012, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of February 27, 2012, by and among the Registrant, Project Plasma Holdings Corporation and Project Plasma Merger Corp., a wholly owned subsidiary of Project Plasma Holdings Corporation, Project Plasma Merger Corp. merged with and into the Registrant, and the Registrant became a wholly owned subsidiary of Project Plasma Holdings Corporation (the “Merger”). As a result of the Merger, the offering pursuant to the Registration Statement has been terminated. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the shares of Common Stock registered under the Registration Statement that remain unsold at the termination of the offering, the Registrant hereby removes from registration the shares of Common Stock registered but unsold under the Registration Statement.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective No. 2 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Milford, The Commonwealth of Massachusetts, on this 20th day of April, 2012.

 

  SERACARE LIFE SCIENCES, INC.
     
  By:  /s/ Gregory A. Gould
    Gregory A. Gould
    Interim President and Chief Executive Officer,  Chief Financial Officer, Secretary and Treasurer

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 2 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated below.

 

Signature   Title   Date
         
         
/s/ Gregory A. Gould   Interim President and Chief Executive Officer and Chief Financial Officer, Treasurer and Secretary (Principal  Executive, Financial and   April 20, 2012
Gregory A. Gould   Accounting Officer)    
         
/s/ Joseph M. Nemmers, Jr.   Director   April 18, 2012
Joseph M. Nemmers, Jr.        
         
/s/ E. Kevin Hrusovsky   Director   April 19, 2012
E. Kevin Hrusovsky        
         
/s/ Sarah L. Murphy   Director   April 20, 2012
Sarah L. Murphy        
         
/s/ Jill Tillman   Director   April 20, 2012
Jill Tillman        

 

 
 

 

Seracare Life Sciences (NASDAQ:SRLS)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Seracare Life Sciences Charts.
Seracare Life Sciences (NASDAQ:SRLS)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Seracare Life Sciences Charts.